Pacira BioSciences reported a strong third quarter with total revenues of $167.5 million, a 31% increase compared to the third quarter of 2021. The company reported a net loss of $0.7 million, or $(0.02) per share, and an adjusted EBITDA of $55.2 million.
Total revenues reached $167.5 million.
EXPAREL net product sales were $132.6 million.
ZILRETTA net product sales were $26.5 million.
iovera° net product sales were $4.5 million.
Pacira is reiterating its full-year 2022 operating expense guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance